The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

Abstract Background The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC)....

Full description

Bibliographic Details
Main Authors: Mary Jo Fidler, Cristina L. Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine, Ibtihaj Fughhi, Mark Pool, Marta Batus, Philip Bonomi, Jeffrey A. Borgia
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
Biomarker
Serum
Non-small cell lung cancer (NSCLC)
Erlotinib
Luminex
VeriStrat
Online Access:http://link.springer.com/article/10.1186/s12885-018-4193-0

Internet

http://link.springer.com/article/10.1186/s12885-018-4193-0

Similar Items